Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Imaging

Use of MRI as an outcome measure in clinical trials in RA

Nature Reviews Rheumatology volume 8, pages 643–644 (2012)Cite this article

Subjects

Following a decade of substantial improvements in sensitivity and usability, MRI is increasingly used to assess primary outcomes of therapeutic trials in rheumatoid arthritis (RA). In the wake of an MRI-based evaluation of treatment efficacy, what lessons are emerging about the clinical value of this technique for patients with RA?

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Conaghan, P. G. et al. Impact of intravenous abatacept on synovitis, osteitis and structural damage in patients with rheumatoid arthritis and an inadequate response to methotrexate: the ASSET randomised controlled trial. Ann. Rheum. Dis. http://dx.doi.org/10.1136/annrheumdis-2012-201611.

  2. Haavardsholm, E. A. et al. Monitoring anti-TNFα treatment in rheumatoid arthritis: responsiveness of magnetic resonance imaging and ultrasonography of the dominant wrist joint compared with conventional measures of disease activity and structural damage. Ann. Rheum. Dis. 68, 1572–1579 (2009).

    Article  CAS  Google Scholar 

  3. Gandjbakhch, F. et al. Synovitis and osteitis are very frequent in rheumatoid arthritis clinical remission: results from an MRI study of 294 patients in clinical remission or low disease activity state. J. Rheumatol. 38, 2039–2044 (2011).

    Article  Google Scholar 

  4. Hetland, M. L. et al. MRI bone oedema is the strongest predictor of subsequent radiographic progression in early rheumatoid arthritis. Results from a 2-year randomised controlled trial (CIMESTRA). Ann. Rheum. Dis. 68, 384–390 (2009).

    Article  CAS  Google Scholar 

  5. Døhn, U. M. et al. No overall progression and occasional repair of erosions despite persistent inflammation in adalimumab-treated rheumatoid arthritis patients: results from a longitudinal comparative MRI, ultrasonography, CT and radiography study. Ann. Rheum. Dis. 70, 252–258 (2011).

    Article  Google Scholar 

  6. Bruynesteyn, K., Boers, M., Kostense P, van der Linden S, van der Heijde, D. Deciding on progression of joint damage in paired films of individual patients: smallest detectable difference or change. Ann. Rheum. Dis. 64, 179–182 (2005).

    Article  CAS  Google Scholar 

  7. Østergaard, M. et al. Significant improvement in synovitis, osteitis, and bone erosion following golimumab and methotrexate combination therapy as compared with methotrexate alone: a magnetic resonance imaging study of 318 methotrexate-naive rheumatoid arthritis patients. Arthritis Rheum. 63, 3712–3722 (2011).

    Article  Google Scholar 

  8. Conaghan, P. G. et al. Assessment by MRI of inflammation and damage in rheumatoid arthritis patients with methotrexate inadequate response receiving golimumab: results of the GO-FORWARD trial. Ann. Rheum. Dis. 70, 1968–1974 (2011).

    Article  CAS  Google Scholar 

  9. van den Broek, M. et al. Rapid radiological progression in the first year of early rheumatoid arthritis is predictive of disability and joint damage progression during 8 years of follow-up. Ann. Rheum. Dis. 71, 1530–1533 (2012).

    Article  CAS  Google Scholar 

  10. Emery, P. et al. Exploratory analyses of the association of MRI with clinical, laboratory and radiographic findings in patients with rheumatoid arthritis. Ann. Rheum. Dis. 70, 2126–2130 (2011).

    Article  Google Scholar 

Download references

Acknowledgements

The author wishes to acknowledge financial support from the Netherlands Organisation for Scientific Research, through a Vidi-grant.

Author information

Authors and Affiliations

  1. Department of Rheumatology, Leiden University Medical Centre, P. O. Box 9600, Leiden, 2300 RC, The Netherlands

    Annette H. M. van der Helm–van Mil

Authors
  1. Annette H. M. van der Helm–van Mil
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

van der Helm–van Mil, A. Use of MRI as an outcome measure in clinical trials in RA. Nat Rev Rheumatol 8, 643–644 (2012). https://doi.org/10.1038/nrrheum.2012.182

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrrheum.2012.182

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing